Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

CNS Tumors

Therapeutic area intelligence for CNS Tumors with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 5
Catalysts: 0
Companies: 2

Companies

pharma companies in oncology →

SYHA Pharmaceuticals →

Assets

Recent signals(5)

ClinicalAugust 3, 2026

Phase I Trial of ONC206 for Newly Diagnosed and Recurrent Malignant CNS Tumors

A phase I trial is investigating ONC206's efficacy in treating newly diagnosed and recurrent diffuse midline gliomas.

ClinicalJuly 9, 2026

NCI Launches Study on Outcomes and Risks of Rare CNS Tumors

The National Cancer Institute is conducting a study to assess outcomes and risks in patients with 12 rare CNS tumors.

ClinicalJune 26, 2026

Age and Treatment Modality Impact Survival in Atypical Meningioma Patients

The study highlights that age influences treatment decisions and survival outcomes in atypical meningioma patients.

ClinicalJune 19, 2026

NCI Launches Study on Natural History of CNS Tumors to Enhance Treatment Options

The National Cancer Institute is conducting a study to better understand brain and spinal cord tumors and improve treatment options.

ClinicalJune 17, 2026

Phase III Trial of SYHA1813 Shows Promise for High-Grade Meningiomas

A Phase III study is underway to evaluate SYHA1813 against investigator's choice treatment in high-grade meningioma patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.